FY2025 EPS Estimates for Kura Oncology Raised by Analyst

Kura Oncology, Inc. (NASDAQ:KURA) – Equities researchers at Brookline Capital Management raised their FY2025 earnings per share estimates for Kura Oncology in a report issued on Thursday, November 21st. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings of ($1.74) per share for the year, up from their prior estimate of ($2.27). The consensus estimate for Kura Oncology’s current full-year earnings is ($2.42) per share. Brookline Capital Management also issued estimates for Kura Oncology’s FY2026 earnings at $0.95 EPS, FY2027 earnings at $3.16 EPS and FY2028 earnings at $5.97 EPS.

Several other analysts also recently weighed in on KURA. Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a report on Tuesday, October 22nd. Wedbush reiterated an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a report on Monday, November 4th. JMP Securities reiterated a “market outperform” rating and set a $32.00 price target on shares of Kura Oncology in a research report on Tuesday, November 19th. UBS Group assumed coverage on Kura Oncology in a research note on Thursday, October 24th. They set a “buy” rating and a $27.00 price target on the stock. Finally, HC Wainwright raised their price objective on Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, November 21st. One analyst has rated the stock with a sell rating, one has given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Kura Oncology has a consensus rating of “Moderate Buy” and an average target price of $29.38.

Kura Oncology Stock Performance

Shares of KURA opened at $10.96 on Monday. The stock has a market capitalization of $852.25 million, a P/E ratio of -4.64 and a beta of 0.86. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. Kura Oncology has a 1 year low of $9.06 and a 1 year high of $24.17. The company’s fifty day moving average is $17.88 and its two-hundred day moving average is $19.67.

Hedge Funds Weigh In On Kura Oncology

Institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC purchased a new stake in Kura Oncology in the 1st quarter valued at about $110,000. Vanguard Group Inc. increased its position in Kura Oncology by 0.7% during the first quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after purchasing an additional 28,212 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Kura Oncology by 17.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 20,148 shares of the company’s stock worth $430,000 after purchasing an additional 2,940 shares during the period. Artal Group S.A. raised its stake in Kura Oncology by 8.6% during the first quarter. Artal Group S.A. now owns 1,919,884 shares of the company’s stock worth $40,951,000 after purchasing an additional 151,828 shares during the period. Finally, Harbor Capital Advisors Inc. boosted its holdings in Kura Oncology by 25.6% in the second quarter. Harbor Capital Advisors Inc. now owns 38,790 shares of the company’s stock valued at $799,000 after acquiring an additional 7,899 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.